Link To Us Link To Us

Bookmark Us Bookmark Us

Supplier Login Supplier Login

Linscott's Directory of Immunological & Biological Reagents
CAYMAN CHEMICAL COMPANY
 (http://www.caymanchem.com)

CAYMAN CHEMICAL COMPANY

1180 East Ellsworth Road

Ann Arbor MI 48108

Phone: (734) 971-3335

Phone: (800) 364-9897 (USA & Canada only)

Fax: (734) 971-3640

Customer Service: custserv@caymanchem.com
Technical Support: techserv@caymanchem.com
Sales: sales@caymanchem.com

Website: http://www.caymanchem.com

 
 
CAYMAN CHEMICAL COMPANY Products - Page 194 of 719
Page 194 of 719
Records 4,826 - 4,850 of 17,965
Name Description Size Catalog #
AG-82 An inhibitor of EGF receptor kinase with an IC50 value of 3 µM in the human epidermoid carcinoma cell line A431 25 mg 10010312-25
AG-82 An inhibitor of EGF receptor kinase with an IC50 value of 3 µM in the human epidermoid carcinoma cell line A431 5 mg 10010312-5
AG-82 An inhibitor of EGF receptor kinase with an IC50 value of 3 µM in the human epidermoid carcinoma cell line A431 50 mg 10010312-50
AG-825 A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER-2/neu (IC50 = 0.35 µM) 1 mg 10010243-1
AG-825 A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER-2/neu (IC50 = 0.35 µM) 10 mg 10010243-10
AG-825 A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER-2/neu (IC50 = 0.35 µM) 5 mg 10010243-5
AG-825 A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER-2/neu (IC50 = 0.35 µM) 50 mg 10010243-50
AG-879 A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 ~0.5 µM), and the VEGF receptor FLK-1 (IC50 ~1 µM) 10 mg 10793-10
AG-879 A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 ~0.5 µM), and the VEGF receptor FLK-1 (IC50 ~1 µM) 25 mg 10793-25
AG-879 A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 ~0.5 µM), and the VEGF receptor FLK-1 (IC50 ~1 µM) 5 mg 10793-5
AG-879 A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 ~0.5 µM), and the VEGF receptor FLK-1 (IC50 ~1 µM) 50 mg 10793-50
AG-99 AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. 10 mg 10010313-10
AG-99 AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. 25 mg 10010313-25
AG-99 AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. 5 mg 10010313-5
AG-99 AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. 50 mg 10010313-50
AGI-5198 Selective inhibitor of IDH1 R132H and R132C mutants in vitro (IC50s = 0.07 and 0.16 µM, respectively) but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 µM); anti-tumor efficacy in vitro and in vivo; induces demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation 1 mg 14624-1
AGI-5198 Selective inhibitor of IDH1 R132H and R132C mutants in vitro (IC50s = 0.07 and 0.16 µM, respectively) but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 µM); anti-tumor efficacy in vitro and in vivo; induces demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation 10 mg 14624-10
AGI-5198 Selective inhibitor of IDH1 R132H and R132C mutants in vitro (IC50s = 0.07 and 0.16 µM, respectively) but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 µM); anti-tumor efficacy in vitro and in vivo; induces demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation 25 mg 14624-25
AGI-5198 Selective inhibitor of IDH1 R132H and R132C mutants in vitro (IC50s = 0.07 and 0.16 µM, respectively) but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 µM); anti-tumor efficacy in vitro and in vivo; induces demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation 5 mg 14624-5
AGI-6780 A potent, selective inhibitor of mutant IDH2 (IC50 = 23 nM) that inhibits 2-HG formation in human glioblastoma U87 and TF-1 cells expressing IDH2-R140Q (IC50s = 11 and 18 nM, respectively); suppresses cell growth of primary human AML cells and induces differentiation of immature blast cells towards macrophage and granulocytic lineages 1 mg 14639-1
AGI-6780 A potent, selective inhibitor of mutant IDH2 (IC50 = 23 nM) that inhibits 2-HG formation in human glioblastoma U87 and TF-1 cells expressing IDH2-R140Q (IC50s = 11 and 18 nM, respectively); suppresses cell growth of primary human AML cells and induces differentiation of immature blast cells towards macrophage and granulocytic lineages 10 mg 14639-10
AGI-6780 A potent, selective inhibitor of mutant IDH2 (IC50 = 23 nM) that inhibits 2-HG formation in human glioblastoma U87 and TF-1 cells expressing IDH2-R140Q (IC50s = 11 and 18 nM, respectively); suppresses cell growth of primary human AML cells and induces differentiation of immature blast cells towards macrophage and granulocytic lineages 5 mg 14639-5
AGK2 A cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 µM) that minimally affects either SIRT1 or SIRT3; rescues dopamine neurons from alpha-synuclein toxicity in both in vitro and in vivo Parkinson's disease models 1 mg 13145-1
AGK2 A cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 µM) that minimally affects either SIRT1 or SIRT3; rescues dopamine neurons from alpha-synuclein toxicity in both in vitro and in vivo Parkinson's disease models 10 mg 13145-10
AGK2 A cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 µM) that minimally affects either SIRT1 or SIRT3; rescues dopamine neurons from alpha-synuclein toxicity in both in vitro and in vivo Parkinson's disease models 25 mg 13145-25
© 1980 - 2014 Linscott's Directory, Linscott's USA. All rights reserved.